Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages

International Journal of Pharmaceutics

Volumn 250, Issue 2, 2003, Pages 403-414

  Salem, Isam Ismail ^a,b   Düzgünes, Nejat ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Clarithromycin cyclodextrin; Efficacy; HPLC; Liposomes; Macrophages; Mycobacterium; Solubility

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; CYCLODEXTRIN; LIPOSOME; WATER;

ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; MACROPHAGE; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RADIOMETRY;

CLARITHROMYCIN; CYCLODEXTRINS; DRUG COMPOUNDING; HUMANS; LIPOSOMES; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM COMPLEX;

EID: 0037448431     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00552-5     Document Type: Article

References (46)

1. Abbott Laboratories, 1996. Biaxin (clarithromycin) Filmtab tablets and granules for oral suspension prescribing information. Abbott Park, IL.
2. Alvarez-Elcoro S., Enzler M.J. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin. Proc. 6:1999;613-634.
3. Ashtekar D., Düzgünes N., Gangadharam P.R.J. Activity of free and liposome-encapsulated streptomycin against Mycobacterium avium complex (MAC) inside peritoneal macrophages. J. Antimicrob. Chemother. 28:1991;615-617.
4. Barradell L.B., Plosker G.L., McTavish D. Clarithromycin: a review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immunodeficiency syndrome. Drugs. 2:1993;289-312.
5. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 234:1959;466-468.
6. Bartley P.B., Allworth A.M., Eisen D.P. Mycobacterium avium complex causing endobronchial disease in AIDS patients after partial immune restoration. Int. J. Tuberculosis Lung Dis. 12:1999;1132-1136.
7. Chin D.P., Reingold A.L., Stone E.N., Vittinghoff E., Horsburgh C.R. Jr, Simon E.M., Yajko D.M., Hadley W.K., Ostroff S.M., Hopewell P.C. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients: a prospective study. J. Infect. Dis. 170:1994;578-584.
8. Cramer F., Saenger W., Spatz H.C. Inclusion compounds. XIX. The formation of inclusion compounds of α-cyclodextrin in aqueous solutions. Thermodynamics and kinetics. J. Am. Chem. Soc. 1:1967;14-20.
9. Crowle A.J., Dahl R., Ross E., May M.H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect. Immun. 59:1991;1823-1831.
10. Dautzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res. Microbiol. 145:1994;197-206.
11. Duchene D. Cyclodextrin and Their Industrial Uses. 1987;Editions de Santé Paris.
12. Düzgünes N. Treatment of human immunodeficiency virus, Mycobacterium avium and Mycobacterium tuberculosis infections by liposome-encapsulated drugs. Lasic D.D., Papahadjopoulos D. Medical Applications of Liposomes. 1998;189-219 Elsevier, Amsterdam.
13. Düzgünes N., Ashteker D.R., Flasher D., et al. Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J. Infect. Dis. 164:1991;143-151.
14. Düzgünes N., Flasher D., Reddy M.V., Luna-Herrera J., et al. Treatment of Mycobacterium avium-intracellulare complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob. Agents Chemother. 11:1996;2618-2621.
15. Eng R.H., Bishburg E., Smith S.M., Mangia A. Diagnosis of Mycobacterium bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. J. Clin. Microbiol. 27:1989;768-769.
16. Fernandes P.B., Hardy D.J., McDaniel D., Hanson C.W., Swanson R.N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob. Agents Chemother. 33:1989;1531-1534.
17. Furney S.K., Skinner P.S., Farrer J., Orme I.M. Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in mouse model. J. Antimicrob. Chemother. 3:1995;786-789.
18. Gangadharam P.R., Ashtekar D.A., Ghori N., Goldstein J.A., Debs R.J., Düzgünes N. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J. Antimicrob. Chemother. 3:1991;425-435.
19. Gangadharam P.R., Ashtekar D.R., Flasher D., Düzgünes N. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob. Agents Chemother. 3:1995;725-730.
20. Heifets L., Mor N., Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. J. Antimicrob. Chemother. 11:1993;2364-2370.
21. Hersey A., Robinson B.H., Kelley H.C. Mechanism of inclusion compound formation for binding of organic dyes, ions, and surfactants to α-cyclodextrin studied by kinetic methods based on competition experiments. J. Chem. Soc. Faraday Trans. 5:1986;1271-1287.
22. Hewitt R.G., Papandonatos G.D., Shelton M.J., et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. AIDS. 13:1999;1367-1372.
23. Horsburgh C.R. Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. New Engl. J. Med. 324:1991;1332-1338.
24. Horsburgh C.R. Jr. The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS. J. Infect. Dis. 3:1999;S461-465.
25. Inderlied C.B., Kemper C.A., Bermudez L.E.M. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6:1993;266-310.
26. Kesavalu L., Goldstein J.A., Debs R.J., Düzgünes N., Gangadharam P.R.J. Differential effects of free and liposome encapsulated amikacin on the growth of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle. 71:1990;215-218.
27. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1996;1017-1025.
28. Majumdar S., Flasher D., Friend D.S., Nassos P., Yajko D., Hadley W.K., Düzgünes N. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infection in human peripheral blood monocyte/macrophages. Antimicrob. Agents Chemother. 12:1992;2808-2815.
29. Mor N., Heifets L. Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. Antimicrob. Agents Chemother. 37:1993;1380-1382.
30. Mor N., Vanderkolk J., Mezo N., Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. Antimicrob. Agents Chemother. 12:1994;2738-2742.
31. Naik S., Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob. Agents Chemother. 33:1989;1614-1616.
32. Oh Y.K., Straubinger R.M. Intracellular fate of Mycobacterium avium: use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization on phagosomal pH and phagosome-lysosome interaction. Infect. Immun. 64:1996;319-325.
33. Oh Y.K., Nix D.E., Straubinger R.M. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob. Agents Chemother. 9:1995;2104-2111.
34. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Pocidalo J.J., Vilde J.L. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. J. Antimicrob. Chemother. 8:1990;1508-1511.
35. Piscitelli S.C., Danziger L.H., Rodvold K.A. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. 11:1992;137-152.
36. Popescu M.C., Swenson E., Ginsberg R.S. Liposome-mediated treatment of viral, bacterial and protozoal infections. Ostro M.J. Liposomes: from Biophysics to Therapeutics. 1987;219-251 Marcel Dekker, New York, NY.
37. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrin. 2. In vivo drug delivery. J. Pharm. Sci. 85:1996;1142-1169.
38. Rastogi N., Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutanol and rifampin against Mycobacterium avium complex. Antimicrob. Agents Chemother. 35:1991;462-470.
39. Rohrbach R.P., Wojcik J.F. A kinetic investigation of the binding of azo dyes to cyclomaltohexaose. Carbohydr. Res. 2:1981;177-181.
40. Salem I.I. Clarithromycin. Brittain H.G. Analytical Profiles of Drug Substances and Excipients. 24:1996;45-85 Academic Press, San Diego, CA.
41. Salem I.I., Düzgünes N. Enhancement of clarithromycin's water solubility via cyclodextrin complexation and efficacy study against Mycobacterium avium complex. Torres-Labandeira J.J., Vila-Jato J.L. Proceedings of the Ninth International Symposium on Cyclodextrins, Santiago de Compostela, Spain, May 31-June 3 1998. 1999;195 Kluwer Academic Publishers, Dordrecht.
42. Schaible U.E., Sturgill-Koszycki S., Schlesinger P.H., Russell D.G. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosome in murine macrophages. J. Immunol. 160:1998;1290-1296.
43. Siddiqi S., Libonati J.P., Middlebrook G. Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Microbiol. 13:1981;908-913.
44. Spencer P.M., Jackson G.G. Fungal and mycobacterial infections in patients infected with the human immunodeficiency virus. J. Antimicrob. Chemother. 23:(Suppl. A):1989;107-125.
45. Steffan, G., Salem, I.I., Düzgünes, N., 2002. Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung. German Patent DE19814814C2.
46. Uekama K., Hirayama F., Irie T. Application of cyclodextrins in pharmaceutical preparations. Drug Target. Deliv. 3:1994;411-456.